"Designing Growth Strategies is in our DNA"
Anthrax is a zoonotic disease caused by the gram-positive bar Bacillus anthracis. Most instances of Bacillus anthracis are cutaneous (95%), the rest of the cases are inhalational (less than 5%) and gastrointestinal (less than 1%). When spores get into the body through inhalation, a cut or scrape in the skin or contaminated food or water, people get infected with anthrax.
Antibiotics like penicillin, doxycycline, and ciprofloxacin are used to treat all types of anthrax. In 2000, Ciprofloxacin (Cipro) was approved by the U.S. Food and Drug Administration for treating individuals who have been exposed to inhalational Bacillus anthracis. Anthrax Vaccine Adsorbed (AVA) or BioThraxTM is indicated for active immunization for the prevention of disease caused by Bacillus anthracis. It is the only FDA approved vaccine for Anthrax
Research institutes have focussed on studying and developing new options for the treatment or prevention of anthrax. For instance; PA83-FhCMB, which is being studied by Fraunhofer, Center for Molecular Biotechnology, is currently in phase-1 clinical trials for the study of plant-derived Recombinant Protective Antigen (rPA) anthrax vaccine. Emergent BioSolutions Inc. is currently studying AV7909 as a third generation anthrax vaccine candidate in Phase 3 trials.
To know how our report can help streamline your business, Speak to Analyst
At present more than 70% of the pipeline candidates for anthrax are in phase 1. Majority of the studies have been sponsored by research institutions.
The report on ‘Anthrax – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Anthrax. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Anthrax.
The report on ‘Anthrax – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.